Live tracker · Updated September 17, 2026
GLP-1 supply
and prices.
Shortages, the compounding wind-down and the price board — the moving parts of the biggest peptide market, dated and logged.
Live page — market changes are logged below with dates
Status board
| Question | Status, September 17, 2026 |
|---|---|
| Semaglutide shortage | Resolved — brand supply recovered |
| Tirzepatide shortage | Resolved — brand supply recovered |
| Mass compounded copies | Ended with the shortage listings; FDA enforcing against mass marketing |
| Patient-specific compounding | Continues in narrower lawful forms via licensed pharmacies |
| Advertised compounded prices | $99 to $400 a month, verified low $99 first month at Eden |
| Brand pen prices | $1000 to $1350 before manufacturer savings programs |
What changed
September 17, 2026 — tracker launched
Board compiled at launch: both major shortages resolved, mass compounding era closed, patient-specific compounding continuing, prices logged in the September index edition.
Questions people ask
Is semaglutide still in shortage?
No — resolved, which is exactly why the mass-compounding era ended. The semaglutide guide covers what remains lawful.
Is compounded semaglutide going away?
The mass-copy version did. Narrower patient-specific compounding continues through licensed pharmacies with individual prescriptions.
Are GLP-1 prices falling?
Compounded offers cluster near $99 to $400 monthly and brands near $1000 to $1350 before savings. Each monthly index edition logs the direction.
Sources: FDA on compounded GLP-1s · FDA shortage data